CAMBRIDGE, England–(BUSINESS WIRE)–Mogrify Limited (Mogrify®), a regenerative medicine company developing a novel class of in vivo reprogramming therapies, today announced it will present preclinical proof-of-concept data at FLORetina-ICOOR 2026. The data support its first-in-class therapy designed to protect and regenerate the retina in patients with retinal disorders. The company’s lead program uses transcription factor-mediated direct reprogramming to convert müller glial cells into functi